Novel antibodies detect additional α-synuclein pathology in synucleinopathies: potential development for immunotherapyJacqui Nimmo, James A. R. Nicoll, Jimmy Savistchenko et al.|Alzheimer s Research & Therapy|2020Cited by 48
Amyloid-β and α-Synuclein Immunotherapy: From Experimental Studies to Clinical TrialsJacqui Nimmo, Jean‐Cosme Dodart, Ajay Verma et al.|Frontiers in Neuroscience|2021Cited by 40
Immunisation with UB-312 in the Thy1SNCA mouse prevents motor performance deficits and oligomeric α-synuclein accumulation in the brain and gutJacqui Nimmo, Roxana O. Carare, Harry Smith et al.|Acta Neuropathologica|2021Cited by 33
Peri‐arterial pathways for clearance of α‐Synuclein and tau from the brain: Implications for the pathogenesis of dementias and for immunotherapyJacqui Nimmo, Roxana O. Carare, David A. Johnston et al.|Alzheimer s & Dementia Diagnosis Assessment & Disease Monitoring|2020Cited by 24
Correction: Novel antibodies detect additional α-synuclein pathology in synucleinopathies: potential development for immunotherapyJacqui Nimmo, James A. R. Nicoll, Ronald Melki et al.|Alzheimer s Research & Therapy|2023Cited by 2